POLYPEPTIDE GROUP AG |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 30.65 CHF | +2.85% |
|
+1.16% | +74.94% |
| Mar. 12 | PolyPeptide Group AG Provides Earnings Guidance for 2024 | CI |
| Mar. 12 | Transcript : PolyPeptide Group AG, 2023 Earnings Call, Mar 12, 2024 |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Take advantage of the offer
* See conditions on site
| Sales 2024 * | 349M 375M 341M | Sales 2025 * | 411M 442M 401M | Capitalization | 1.03B 1.11B 1.01B |
|---|---|---|---|---|---|
| Net income 2024 * | -12M -12.89M -11.72M | Net income 2025 * | 14M 15.04M 13.67M | EV / Sales 2024 * | 3.23 x |
| Net Debt 2024 * | 93.57M 100M 91.37M | Net Debt 2025 * | 116M 125M 113M | EV / Sales 2025 * | 2.8 x |
| P/E ratio 2024 * |
-104
x | P/E ratio 2025 * |
61.1
x | Employees | 1,273 |
| Yield 2024 * |
-
| Yield 2025 * |
0.14% | Free-Float | 39.12% |
More Fundamentals
* Assessed data
More news
Latest transcript on PolyPeptide Group AG
More press releases
More news
| 1 day | +2.85% | ||
| 1 week | +1.16% | ||
| Current month | +1.16% | ||
| 1 month | +7.17% | ||
| 3 months | +100.46% | ||
| 6 months | +50.84% | ||
| Current year | +74.94% |
1 week
28.45
31.50
1 month
27.7531.50
Current year
14.1131.50
1 year
14.1131.50
3 years
14.11147.40
5 years
14.11147.40
10 years
14.11147.40
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 52 | 23-04-11 | |
| Chief Tech/Sci/R&D Officer | 52 | 11-12-31 | |
Jens Fricke
COO | Chief Operating Officer | 59 | 22-11-30 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 70 | 20-12-31 | |
Peter Wilden
CHM | Chairman | 67 | 21-03-31 |
Jane Anne Salik
BRD | Director/Board Member | 71 | 05-12-31 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.01% | 0 M€ | -.--% | - | |
| 0.00% | 10 M€ | -3.35% | - | |
| 0.00% | 0 M€ | +3.53% | - | |
| 0.00% | 0 M€ | -3.22% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-07 | 30.65 | +2.85% | 43,763 |
| 24-05-06 | 29.8 | +0.85% | 23,473 |
| 24-05-03 | 29.55 | +1.90% | 21,761 |
| 24-05-02 | 29 | -4.29% | 39,932 |
| 24-04-30 | 30.3 | -0.33% | 21,445 |
Delayed Quote Swiss Exchange, May 07, 2024 at 11:31 am EDT
More quotes
Polypeptide Group AG is a Switzerland-based Contract Development & Manufacturing Organization (CDMO) focusing on proprietary and generic GMP-grade peptides used by pharmaceutical and biotech companies in approved pharmaceutical products, drugs in clinical development as well as in generic products.
Sector
Pharmaceuticals
Calendar
2024-08-12
- Q2 2024 Earnings Call
Trading Rating
Investor Rating
ESG Refinitiv
B-
Sell
Buy
Mean consensus
HOLD
Number of Analysts
5
Last Close Price
31.35
EUR
Average target price
25.12
EUR
Spread / Average Target
-19.87%
EPS Revisions
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +74.94% | 1.11B | |
| +33.43% | 700B | |
| +26.43% | 569B | |
| -5.12% | 358B | |
| +19.59% | 330B | |
| +4.89% | 287B | |
| +14.32% | 236B | |
| +5.79% | 202B | |
| -9.49% | 197B | |
| +4.26% | 161B |
- Stock Market
- Equities
- PPGN Stock